Nicholas A.J. Botwood insider trades
Open-market stock purchases and sales by Nicholas A.J. Botwood, Head of R&D, CMO at Syndax Pharmaceuticals Inc, from SEC Form 4 filings since May 16, 2025.
Track record: 100% of 1 scored buy are up 5% or more since purchase, averaging +89%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Jun 12, 2026 | SNDX Syndax Pharmaceuticals Inc | Sold | $567K |
| Jun 12, 2026 | SNDX Syndax Pharmaceuticals Inc | Bought (not open market) | — |
| Jun 11, 2026 | SNDX Syndax Pharmaceuticals Inc | Sold | $617K |
| Jun 11, 2026 | SNDX Syndax Pharmaceuticals Inc | Bought (not open market) | — |
| Feb 4, 2026 | SNDX Syndax Pharmaceuticals Inc | Bought (not open market) | — |
| Feb 4, 2026 | SNDX Syndax Pharmaceuticals Inc | Bought (not open market) | — |
| Feb 4, 2026 | SNDX Syndax Pharmaceuticals Inc | Bought (not open market) | $3M |
Companies traded
- SNDX Syndax Pharmaceuticals Inc: 1 buy, 2 sales, last Jun 12, 2026
Get free alerts when Nicholas A.J. Botwood files a new trade →